hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mL recall — Ani Pharmaceuticals, Inc. (Class III)

Ani Pharmaceuticals, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mL — a Class III recall, initiated 2026-06-02 and posted to the FDA enforcement report on 2026-07-01, under recall number D-0619-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Presence of foreign substance”. From the product description, the form is oral solution, the strengths given are 10 mg/5 mL and 473 mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 70954-912-10. Distribution is recorded as “Nationwide in the USA” — Nationwide (US), with the recalling firm on record in MN, United States. It is the only recall number the FDA has filed under event ID 99131. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0619-2026
FDA event ID 99131
Classification Class III (least serious regulatory tier)
Status Ongoing
Recalling firm Ani Pharmaceuticals, Inc.
Recall initiated 2026-06-02
Reported by FDA 2026-07-01
Report lag 29 days from initiation to report
Distribution Nationwide in the USA — Nationwide (US)
Firm location on record MN, United States
Product description (source) hydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 473 mL (1 Pint), Rx only, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623. NDC: 70954-912-10

Reason reported by FDA

Presence of foreign substance

4 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

6 identifying values matched by exact pattern in the 24-word product description above; each is a literal substring of it.

Product named hydrOXYzine Hydrochloride Oral Solution
Form Oral Solution
Strength 10 mg/5 mL · 473 mL
NDC 70954-912-10
Marketing category Rx only
Distributed by ANI Pharmaceuticals, Inc.

Other indexed recalls from Ani Pharmaceuticals, Inc.

2 indexed records name Ani Pharmaceuticals, Inc. as the recalling firm, across 2 FDA events, reported 2026-05-27 to 2026-07-01. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Estradiol Gel, 0.1%D-0543-2026Class II0.1% · Gel2026-05-27

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 4 are the Class III ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Fexofenadine Hydrochloride Tablets, 180 mgD-0654-2026Sun Pharmaceutical Industries IncClass III2026-07-08
Lidolog Kit, 2%D-0713-2026Asclemed Usa Inc.Class III2026-07-29
Dabigatran etexilate Capsules, 110 mgD-0735-2026Ascend Laboratories, LLCClass III2026-07-29
Dabigatran etexilate Capsules, 150 mgD-0736-2026Ascend Laboratories, LLCClass III2026-07-29

Nearest Class III recalls by date

25 of 250 indexed records share the Class III tier; the 10 nearest to 2026-07-01 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Focalin XR (dexmethylphenidate HCl) 5 mgD-0608-2026Sandoz Inc5 mg · Extended-Release Capsules2026-06-24
Epinephrine Injection, 1mg/mLD-0581-2026Fresenius Kabi Usa, LLC1mg/mL · Injection2026-06-17
Primidone Tablets, 50 mgD-0585-2026Amneal Pharmaceuticals, LLC50 mg · Tablets2026-06-17
Lidocaine HCl Injection, 2%D-0552-2026Eugia US LLC2% · Injection2026-06-10
Nicotine Transdermal System Patch, 14 mgD-0550-2026Aveva Drug Delivery Systems, Inc.14 mg · Transdermal System2026-06-03
PRED MILD, 0.12%D-0551-2026Abbvie Inc.0.12% · Ophthalmic Suspension2026-06-03
Primidone Tablets USP, 250mgD-0533-2026Lannett Company Inc.250mg · Tablets2026-05-27
Primidone Tablets, 50 mgD-0534-2026Golden State Medical Supply Inc.50 mg · Tablets2026-05-27
Primidone Tablets, 250 mgD-0535-2026Golden State Medical Supply Inc.250 mg · Tablets2026-05-27
Primidone Tablets, 250 mgD-0536-2026Amerisource Health Services LLC250 mg · Tablets2026-05-27

Reading this record

Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 70954-912-10 at the FDA source to confirm it is covered.

Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Ani Pharmaceuticals, Inc. (2 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0619-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0619-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-01
Ingested
2026-08-22
Record hash
2d47154902ab1c08

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.